URGN Earnings

URGN reported its earnings on 2026-05-06, showcasing a revenue of 50.96M against an estimate of 43.57M, resulting in a 16.96% surprise. The EPS was -0.47, surpassing the expected -0.56 by 16.07%. The stock experienced a 10.16% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following URGN's earnings announcement on 2026-05-06, the stock price moved by 10.16% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, URGN's stock price tends to shift by an average of 1.08% in the 10 days leading up to earnings and -1.89% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate URGN's annual revenue to reach 53.26M, while the EPS is projected at -0.35. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between URGN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, URGN's stock price typically moves by 1.08% in the 10 days before its earnings and -1.89% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.35 and revenue of 53.26M.

The earnings call highlights strong financial performance with a 15% revenue increase, driven by JELMYTO and ZUSDURI. Despite net losses, there's improvement due to cost management. Product development is on track, with ZUSDURI and clinical trials progressing as planned. The Q&A session did not reveal significant concerns. However, risks in commercialization and regulatory approvals remain. Overall, the positive financials and strategic focus on growth suggest a likely positive stock reaction, especially given the lack of negative sentiment from analysts.